Blueprint Medicines announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the approval of AYVAKYT for the treatment of adult patients with indolent systemic mastocytosis with moderate to severe symptoms inadequately controlled on symptomatic treatment. Pending European Commission approval, AYVAKYT will become the first and only therapy for people living with ISM in Europe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- Roblox upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Blueprint Medicines upgraded to Outperform from Perform at Oppenheimer
- Blueprint Medicines price target raised to $58 from $46 at Barclays
- Blueprint Medicines reports Q3 EPS ($2.20), consensus ($2.37)
- Blueprint Medicines Reports Third Quarter 2023 Results
